Relative quantification analysis of the <i>GAS5</i> expression level was performed by RQ-PCR methodology with the <i>GAPDH</i> gene as endogenous control and by using the comparative ddCt method with control samples as a calibrator.<h4>Results</h4>No significant difference was found between plasma expression <i>GAS5</i> in MM patients (median 0.833, range 0.013-3.678) and <i>GAS5</i> expression in healthy control samples (median 1, range 0.49-2.668) (p=0.116). This evidence concerns the gene GAS5 and Miyoshi myopathy.